Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Bruno Zilberstein, Carlos Malheiros, Laercio Gomes Lourenço, Paulo Kassab, Carlos Eduardo Jacob, Antonio Carlos Weston, Cláudio José Caldas Bresciani, Osvaldo Castro, Joaquim Gama-Rodrigues, Aldenis Albaneze Borin, Carlos Buchpiegel, André Montagnini, Celso Vieira Leite, Claudio Roberto Deutsch, Cleber Dario Pinto Kruel, Donato Mucerino, Durval Wohnrath, Elias Ilias, Fátima Mrué, Fauze Maluf-Filho, Felipe Rocha, Fernando de Souza, Flávio Saavedra Tomasich, Geraldo Ishak, Gustavo Laporte, Hamilton Petry de Souza, Ivan Cecconello, Jaime Eisig, Jorge Ohana, Jorge Sabagga, José Carlos del Grande, José Paulo de Jesus, José Soares, Luis Antonio Negrão Dias, Luiz Fernando Moreira, Mariangela Correa, Marineide Carvalho, Nelson Adami Andreollo, Nelson Dell Áquila, Nicolau Gregori Czeczko, Nicolau Kruel, Nora Manoukian Forones, Orlando Milhomem da Motta, Osvaldo Malafaia, Paulo Assumpção, Paulo Leonardi, Paulo Sakai, Paulo Roberto Savassi Rocha, Ramiro Colleoni, Roberto Gurgel, Roberto Pelegrini Coral, Sidney Chalub, Ulisses Ribeiro- Junior, Venancio Avancini Ferreira Alves, Vinicius de Lima Vasquez, Vladimir Nadalin
BACKGROUND: In Brazil, gastric cancer is the fourth most common malignancy among men and sixth among women. The cause is multivariate and the risks are well known. It has prognosis and treatment defined by the location and staging of the tumor and number of lymph nodes resected and involved. AIM: The Brazilian Consensus on Gastric Cancer promoted by ABCG was designed with the intention to issue guidelines that can guide medical professionals to care for patients with this disease...
2013: Brazilian Archives of Digestive Surgery: ABCD
#2
REVIEW
David H Ilson
PURPOSE OF REVIEW: The aim of this study was to review studies published within the past year regarding management of gastric cancer. RECENT FINDINGS: Laparoscopic gastrectomy achieves equivalent survival compared with open gastrectomy in early stage and locally advanced gastric cancer. Adjuvant chemotherapy with 6 months of S-1 and oxaliplatin was superior to 12 months of S-1, and the addition of postoperative radiation therapy did not improve survival. The FLOT regimen is the new standard for preoperative chemotherapy...
November 2019: Current Opinion in Gastroenterology
#3
JOURNAL ARTICLE
P G Casali, N Abecassis, H T Aro, S Bauer, R Biagini, S Bielack, S Bonvalot, I Boukovinas, J V M G Bovee, T Brodowicz, J M Broto, A Buonadonna, E De Álava, A P Dei Tos, X G Del Muro, P Dileo, M Eriksson, A Fedenko, V Ferraresi, A Ferrari, S Ferrari, A M Frezza, S Gasperoni, H Gelderblom, T Gil, G Grignani, A Gronchi, R L Haas, B Hassan, P Hohenberger, R Issels, H Joensuu, R L Jones, I Judson, P Jutte, S Kaal, B Kasper, K Kopeckova, D A Krákorová, A Le Cesne, I Lugowska, O Merimsky, M Montemurro, M A Pantaleo, R Piana, P Picci, S Piperno-Neumann, A L Pousa, P Reichardt, M H Robinson, P Rutkowski, A A Safwat, P Schöffski, S Sleijfer, S Stacchiotti, K Sundby Hall, M Unk, F Van Coevorden, W T A van der Graaf, J Whelan, E Wardelmann, O Zaikova, J Y Blay
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#4
RANDOMIZED CONTROLLED TRIAL
Annemieke Cats, Edwin P M Jansen, Nicole C T van Grieken, Karolina Sikorska, Pehr Lind, Marianne Nordsmark, Elma Meershoek-Klein Kranenbarg, Henk Boot, Anouk K Trip, H A Maurits Swellengrebel, Hanneke W M van Laarhoven, Hein Putter, Johanna W van Sandick, Mark I van Berge Henegouwen, Henk H Hartgrink, Harm van Tinteren, Cornelis J H van de Velde, Marcel Verheij
BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies have not been investigated in a head to head comparison. We aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma. METHODS: In this investigator-initiated, open-label, randomised phase 3 trial, we enrolled patients aged 18 years or older who had stage IB- IVA resectable gastric or gastro-oesophageal adenocarcinoma (as defined by the American Joint Committee on Cancer, sixth edition), with a WHO performance status of 0 or 1, and adequate cardiac, bone marrow, liver, and kidney function...
May 2018: Lancet Oncology
#5
REVIEW
Andrés Poveda, Xavier García Del Muro, Jose Antonio López-Guerrero, Ricardo Cubedo, Virginia Martínez, Ignacio Romero, César Serrano, Claudia Valverde, Javier Martín-Broto
Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1). On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum. GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists…) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours...
April 2017: Cancer Treatment Reviews
#6
JOURNAL ARTICLE
Jennifer Y Wo, Sam S Yoon, Alexander R Guimaraes, John Wolfgang, Harvey J Mamon, Theodore S Hong
PURPOSE: To develop a contouring atlas of the gastric lymph node stations to be used in defining and planning clinical target volumes in 3-dimensional treatment planning for gastric cancers. METHODS AND MATERIALS: Four physicians, including 2 radiation oncologists, a diagnostic radiologist, and a surgical oncologist specialized in gastric cancer, convened over the course of multiple meetings. Four patients were identified as representative cases, including 3 gastric cancer patients treated with differing surgical approaches (total gastrectomy, Ivor-Lewis esophagogastrectomy, and distal gastrectomy) and 1 patient with intact gastric anatomy...
January 2013: Practical Radiation Oncology
#7
REVIEW
Eric Van Cutsem, Xavier Sagaert, Baki Topal, Karin Haustermans, Hans Prenen
Gastric cancer is one of the leading causes of cancer-related death worldwide. Many patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Gastric cancer is separated anatomically into true gastric adenocarcinomas and gastro-oesophageal-junction adenocarcinomas, and histologically into diffuse and intestinal types. Gastric cancer should be treated by teams of experts from different disciplines. Surgery is the only curative treatment. For locally advanced disease, adjuvant or neoadjuvant therapy is usually implemented in combination with surgery...
November 26, 2016: Lancet
#8
REVIEW
Joseph M Pepek, Christopher G Willett, Brian G Czito
Contemporary randomized trials have demonstrated that radiation therapy combined with chemotherapy and surgery improves survival in both the neoadjuvant and adjuvant treatment of gastroesophageal cancers. Consequently, radiation treatment planning and administration have taken on an added importance to ensure optimal outcomes as well as minimize treatment-related morbidity. This article highlights recent technical advances and considerations for radiation therapy planning for gastroesophageal junction tumors...
January 2013: Seminars in Radiation Oncology
#9
MULTICENTER STUDY
Stefan Welz, Thomas Hehr, Christian Kollmannsberger, Carsten Bokemeyer, Claus Belka, Wilfried Budach
PURPOSE: Adjuvant, 5-fluorouracil (5-FU)-based chemoradiotherapy for completely resected high-risk gastric adenocarcinoma has been shown to improve survival in a randomized Intergroup trial. However, the results still showed an unsatisfactory outcome. On the basis of previously reported results of a Phase II trial using a more aggressive, cisplatin-containing chemoradiotherapy schedule, we investigated the effects of this approach on long-term renal function. PATIENTS AND METHODS: Between December 2000 and September 2003, 27 patients were treated at Tübingen University in a Phase II multicenter trial investigating adjuvant chemoradiotherapy...
December 1, 2007: International Journal of Radiation Oncology, Biology, Physics
#10
RANDOMIZED CONTROLLED TRIAL
Jeong Il Yu, Do Hoon Lim, Yong Chan Ahn, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Seung Tae Kim, Sung Kim, Tae Sung Sohn, Min Gew Choi, Jae Moon Bae, Heerim Nam
PURPOSE: We investigated which subgroups might benefit from adjuvant radiotherapy (RT) and suggested optimal RT targets by analyzing the results of the Adjuvant Chemoradiation Therapy in Stomach Cancer (ARTIST) trial. METHODS: We conducted randomized controlled trial in 458 gastric cancer patients. Patients were randomly assigned to XP (6 cycles of capecitabine and) or XPRT (2 cycles of XP+RT 45Gy/25 fraction with capecitabine+2 cycles of XP) groups after D2 resection...
October 2015: Radiotherapy and Oncology
#11
EDITORIAL
Karyn A Goodman
No abstract text is available yet for this article.
October 1, 2015: Journal of Clinical Oncology
#12
RANDOMIZED CONTROLLED TRIAL
Jeeyun Lee, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Tae Sung Sohn, Jae Hyung Noh, Jae Moon Bae, Yong Chan Ahn, Insuk Sohn, Sin Ho Jung, Cheol Keun Park, Kyoung-Mee Kim, Won Ki Kang
PURPOSE: The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge to investigate the role of postoperative chemoradiotherapy therapy in patients with curatively resected gastric cancer with D2 lymph node dissection. This trial was designed to compare postoperative treatment with capecitabine plus cisplatin (XP) versus XP plus radiotherapy with capecitabine (XP/XRT/XP). PATIENTS AND METHODS: The XP arm received six cycles of XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks) chemotherapy...
January 20, 2012: Journal of Clinical Oncology
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
